OWC Pharmaceutical Research Corp.

 

Mr. Mordechai Bignitz, Chief Executive Officer and Chairman

motiMr. Mordechai Bignitz has been the CEO and President of OWC Pharmaceutical Research Corp. since July 15, 2014. Mr. Bignitz has extensive experience in the management of investments and financial systems, accounting and taxation. Mr. Bignitz is involved in economic and financial consulting to companies in the field of technoogy. He is a seasoned financial manager, with over 30 years’ experience in investment management, specializing in all aspects of the planning and execution of deals at every level and much more. Mr. Bignitz served as CEO of Geffen Green Energy Ltd. and  as a director of Leader Capital Markets Ltd. (TASE: LDRC) and Leader Holdings & Investments Ltd. (TASE: LDER).

Mr. Bignitz is a CPA, holds a BA in Accounting and Economics from Tel-Aviv University and completed the Executive Program in Management and Strategy in Retail at Babson College in Boston.

 

Mr. Jeffrey Friedland – Advisory Board Member 

Mr. Jeffrey Friedland is an emerging market pioneer. Friedland Global Capital Pte Ltd. was one of the first American investment banks to establish a presence in China, and he can now be found on the forefront of the global cannabis industry as an investor as well as business owner.

In his book “Marijuana: The World’s Most Misunderstood Plant”, Mr. Friedland dives into the world of medical marijuana, discussing the plants history, what we know and what we still hope to discover. Mr. Friedland has been a frequent speaker at conferences and events, including speeches to individual and institutional investors on investments, emerging markets, and the global cannabis industry.

 

Ms. Miriam (Miri) Sani, MSc Eng. – Advisory Board Member

Ms. Sani, who received an MSc [Master of Science Degree) in Chemistry from the Technion – Israel Institute of Technology, Haifa, Israel, will advise OWC’s management on the transition of its innovatively-developed cannabinoid products and delivery systems developed internally and through its hospital relationships, to full industrial and commercial production, in strict compliance with all local and state regulations and protocols, working closely with applicable healthcare agencies and ministries. Ms. Sani will also supervise all manufacturing facilities of third party licensees to assure for quality control in accordance with OWC protocols that were developed at leading hospitals in Israel, for a steady and long-lasting quality of products and measured dosages.

Ms. Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OBYOGN and IVD’s through both regulatory affairs and clinical studies.

 

Dr. Sharon Rozenblat – Advisory Board Member

Dr. Rozenblat is tasked with overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company’s efforts to commercialize its cannabis-based formulations and delivery mechanisms.

Ms. Rozenblat earned her Ph.D. in biochemistry and cell biology (Magna Cum Laude) from Bar-Ilan University in Israel. Her research focused on botanical components for Melanoma (skin cancer) treatment. From 2007 to 2015, Dr. Rozenblat served as Chief Scientist at Kamedis ltd., an Israeli-based dermatological company, where she had established and managed the research and development of herbal products for the treatment of dermatological conditions.

Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in a joint venture with Green Mountain Biotech (GMB), in Chengdu, China, where she worked with GMB to find agricultural resources, develop extraction methods, establish quality control methodologies, and conduct safety and efficacy studies.

Dr. Rozenblat serves as a consultant to international organizations, including as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial Research and Development Foundation (KORIL), and the Israel-Singapore Foundation (SIIRD), both of which resulted in numerous products and patents.


 

One World Cannabis Ltd.

 

Mr. Alon Sinai – Chief Operating Officer and Interim Chief Executive Officer 

img_6330-273x300Mr. Sinai is a retired Lieutenant-Colonel from the Medical Corps of IDF (1987-2013), and completed the NATO School Oberammergau program (NATO’s premier individual training and education facility at the operational level). Most recently he served as Head of the Doctrine, Instruction and Training Department, where he was responsible for commanding and developing emergency medical facilities, writing professional doctrine and literature for the IDF Medical Corps and working with foreign militaries.

Mr. Sinai is currently pursuing his Ph.D. in Health Systems Management at Ben-Gurion University of the Negev, where he previously earned an MA in Health Systems Management and a B.EMS in Emergency Medicine.

 

Dr. Med. Yehuda Baruch – Director of Research and Regulatory Affairs

img_63-255x300Dr. Baruch served as Head of the Israeli Ministry of Health’s Medical Marijuana Program from 2003 through 2013 where he spearheaded the efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. He has extensive experience in researching medical cannabis, most notably for its effect on PTSD.

From 2004 until recently he served as CEO of Abarbanel Mental Health Center in Bat Yam, Israel. Prior to that, he was the director of Israel’s Ministry of Health medical management division, and director general of Be’er Yakov Mental Health Center. He has taught at Ben-Gurion University of the Negev and Tel Aviv University’s Sackler School of Medicine.

 

Mr. Shmuel De-Saban, CPA (IL) – Chief Finance Officer

img_6277-229x300A Certified Public Accountant, De-Saban brings 19 years of financial experience in various industries to his role in the Company. De-Saban practices as CPA (IL) and runs a full-service CPA firm in Israel. Prior to joining One World Cannabis, De-Saban served as CFO and Controller for several organizations, and acquired experience in US GAAP accounting, SEC reporting, financial planning and analysis, tax and investor relations. De-Saban graduated with a degree in Economics at Tel-Aviv University and Accounting (CPA) at Bar-Ilan University.